Dr. Jonathan Rosenberg discusses the treatment-related side effects of EV/pembro for bladder cancer. Dr. David Braun discusses his organization of immune therapies into four groups and describes novel treatments and targets. Drs. Cristina Suárez, Elena Castro, and María Teresa Bourlon host the first Spanish-language ASCO episode for The Uromigos. Drs. Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden get a chance to win The Uromigos Cup. Drs. Viktor Grünwald, Boris Hadaschik and Gunhild Von Amsberg answer trivia for the Uromigos Cup qualifying round. Dr. Aditya Bagrodia discusses new drugs and studies for NMIBC that were presented at this year's AUA meeting. Silke Gillessen joins Tom and Brian, who give their opinion on new data presented at the conference. Drs. Nobuaki Matsubara, Hiroshi Kitamura and Yuji Miura answer trivia questions set by Tom and Brian for the Uromigos Cup. David McDermott discusses the adjuvant vs neoadjuvant trial and its wider implications for the genitourinary oncology field. Dr. Guru Sonpavde describes the efficacy of chemotherapy with nivolumab in lymph node-only first-line UC patients. Dr. Laurence Albiges discusses this biomarker which may have predictive and prognostic capabilities for kidney cancer. Toni Choueiri and Brian describe similarities and differences in the biomarker findings of the KN426 and CLEAR trials. Dr. Andrea Necchi describes the efficacy and toxicity of neoadjuvant sacituzumab govitecan in urothelial carcinoma. Dr. Jonathan Rosenberg breaks down the data available for the bladder cohort from the DESTINY-PanTumor02 trial. Dr. Alex Wyatt describes the predictive capabilities of ctDNA in determining outcomes in the TheraP trial. Dr. Christos Kyriakopoulos describes the outcome of the CHAARTED-2 study for castration-resistant prostate cancer. Drs. Danny Heng, Christian Kollmannsberger and Kala Sridhar attempt to take on Team LA to win the Uromigos Cup. Silke Gillessen joins Brian and Tom to give a preview of this year's ASCO annual meeting. Dr. Nick James joins the podcast to discuss the recent Lancet Commission paper on prostate cancer. Tom and Brian are joined by David Penson to discuss upcoming presentations to look forward to at AUA.